APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Migraine Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Migraine Drugs Market Outlook and Growth Opportunities 2026

27 December 2025191 pages

Choose your research edition.

Industry ResearchAnti-Migraine Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Migraine Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Anti-Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Migraine Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Migraine Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Anti-Migraine Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Migraine Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Migraine Drugs market include Allergan, Endo, Impax Laboratories, AstraZeneca, Amgen, Bayer, GlaxoSmithKline, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Migraine Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Migraine Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Migraine Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Migraine Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Migraine Drugs Segment by Company

Allergan

Endo

Impax Laboratories

AstraZeneca

Amgen

Bayer

GlaxoSmithKline

Pfizer

Eli Lilly

Merck

Johnson & Johnson

Teva

Eisai

Abbott

Anti-Migraine Drugs Segment by Type

Ergots

Triptans

Others

Anti-Migraine Drugs Segment by Application

Women

Men

Anti-Migraine Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Migraine Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Migraine Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Migraine Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Migraine Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Migraine Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Migraine Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Migraine Drugs industry.

Chapter 3: Detailed analysis of Anti-Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Migraine Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Migraine Drugs Industry Trends Table 2. Anti-Migraine Drugs Industry Drivers Table 3. Anti-Migraine Drugs Industry Opportunities and Challenges Table 4. Anti-Migraine Drugs Industry Restraints Table 5. Global Anti-Migraine Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Migraine Drugs Revenue Share by Company (2021-2026) Table 7. Global Anti-Migraine Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Anti-Migraine Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Migraine Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anti-Migraine Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Migraine Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Migraine Drugs Company, Product Type & Application Table 13. Global Anti-Migraine Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Migraine Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ergots Table 18. Significant Companies of Triptans Table 19. Significant Companies of Others Table 20. Global Anti-Migraine Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Anti-Migraine Drugs Sales Volume by Type (2021-2026) & (W Units) Table 22. Global Anti-Migraine Drugs Sales Volume by Type (2027-2032) & (W Units) Table 23. Global Anti-Migraine Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Anti-Migraine Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Anti-Migraine Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Anti-Migraine Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Anti-Migraine Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Anti-Migraine Drugs Sales Value Share by Type (2021-2026) Table 29. Global Anti-Migraine Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Women Table 31. Significant Companies of Men Table 32. Global Anti-Migraine Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Anti-Migraine Drugs Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Anti-Migraine Drugs Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Anti-Migraine Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Anti-Migraine Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Anti-Migraine Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-Migraine Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Anti-Migraine Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Anti-Migraine Drugs Sales Value Share by Application (2021-2026) Table 41. Global Anti-Migraine Drugs Sales Value Share by Application (2027-2032) Table 42. Global Anti-Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Anti-Migraine Drugs Sales by Region (2021-2026) & (W Units) Table 44. Global Anti-Migraine Drugs Sales Market Share by Region (2021-2026) Table 45. Global Anti-Migraine Drugs Sales by Region (2027-2032) & (W Units) Table 46. Global Anti-Migraine Drugs Sales Market Share by Region (2027-2032) Table 47. Global Anti-Migraine Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-Migraine Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Anti-Migraine Drugs Sales Value Share by Region (2021-2026) Table 50. Global Anti-Migraine Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Anti-Migraine Drugs Sales Value Share by Region (2027-2032) Table 52. Global Anti-Migraine Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Anti-Migraine Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Anti-Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Anti-Migraine Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Anti-Migraine Drugs Sales by Country (2021-2026) & (W Units) Table 57. Global Anti-Migraine Drugs Sales Market Share by Country (2021-2026) Table 58. Global Anti-Migraine Drugs Sales by Country (2027-2032) & (W Units) Table 59. Global Anti-Migraine Drugs Sales Market Share by Country (2027-2032) Table 60. Global Anti-Migraine Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Anti-Migraine Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Anti-Migraine Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Anti-Migraine Drugs Sales Value Market Share by Country (2027-2032) Table 64. Allergan Company Information Table 65. Allergan Business Overview Table 66. Allergan Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Allergan Anti-Migraine Drugs Product Portfolio Table 68. Allergan Recent Development Table 69. Endo Company Information Table 70. Endo Business Overview Table 71. Endo Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Endo Anti-Migraine Drugs Product Portfolio Table 73. Endo Recent Development Table 74. Impax Laboratories Company Information Table 75. Impax Laboratories Business Overview Table 76. Impax Laboratories Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Impax Laboratories Anti-Migraine Drugs Product Portfolio Table 78. Impax Laboratories Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Anti-Migraine Drugs Product Portfolio Table 83. AstraZeneca Recent Development Table 84. Amgen Company Information Table 85. Amgen Business Overview Table 86. Amgen Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Amgen Anti-Migraine Drugs Product Portfolio Table 88. Amgen Recent Development Table 89. Bayer Company Information Table 90. Bayer Business Overview Table 91. Bayer Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Bayer Anti-Migraine Drugs Product Portfolio Table 93. Bayer Recent Development Table 94. GlaxoSmithKline Company Information Table 95. GlaxoSmithKline Business Overview Table 96. GlaxoSmithKline Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. GlaxoSmithKline Anti-Migraine Drugs Product Portfolio Table 98. GlaxoSmithKline Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pfizer Anti-Migraine Drugs Product Portfolio Table 103. Pfizer Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Eli Lilly Anti-Migraine Drugs Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Merck Company Information Table 110. Merck Business Overview Table 111. Merck Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Merck Anti-Migraine Drugs Product Portfolio Table 113. Merck Recent Development Table 114. Johnson & Johnson Company Information Table 115. Johnson & Johnson Business Overview Table 116. Johnson & Johnson Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Johnson & Johnson Anti-Migraine Drugs Product Portfolio Table 118. Johnson & Johnson Recent Development Table 119. Teva Company Information Table 120. Teva Business Overview Table 121. Teva Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Teva Anti-Migraine Drugs Product Portfolio Table 123. Teva Recent Development Table 124. Eisai Company Information Table 125. Eisai Business Overview Table 126. Eisai Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Eisai Anti-Migraine Drugs Product Portfolio Table 128. Eisai Recent Development Table 129. Abbott Company Information Table 130. Abbott Business Overview Table 131. Abbott Anti-Migraine Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Abbott Anti-Migraine Drugs Product Portfolio Table 133. Abbott Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Anti-Migraine Drugs Distributors List Table 137. Anti-Migraine Drugs Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Anti-Migraine Drugs Product Image Figure 2. Global Anti-Migraine Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Migraine Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Migraine Drugs Sales (2021-2032) & (W Units) Figure 5. Global Anti-Migraine Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anti-Migraine Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ergots Image Figure 10. Triptans Image Figure 11. Others Image Figure 12. Global Anti-Migraine Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Anti-Migraine Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Anti-Migraine Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Anti-Migraine Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Anti-Migraine Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Anti-Migraine Drugs Sales Value Share by Type (2021-2032) Figure 18. Women Image Figure 19. Men Image Figure 20. Global Anti-Migraine Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Anti-Migraine Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-Migraine Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Anti-Migraine Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-Migraine Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-Migraine Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Anti-Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Anti-Migraine Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Anti-Migraine Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Anti-Migraine Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Anti-Migraine Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Anti-Migraine Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Anti-Migraine Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Anti-Migraine Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Anti-Migraine Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Anti-Migraine Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Anti-Migraine Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Anti-Migraine Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Anti-Migraine Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Anti-Migraine Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Anti-Migraine Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Anti-Migraine Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Anti-Migraine Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Ergots
  • Triptans
  • Others
Applications
  • Women
  • Men
Companies covered
  • Allergan
  • Endo
  • Impax Laboratories
  • AstraZeneca
  • Amgen
  • Bayer
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck
  • Johnson & Johnson
  • Teva
  • Eisai
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Migraine Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Migraine Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Migraine Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Migraine Drugs Market Dynamics
  1. 2.1 Anti-Migraine Drugs Industry Trends
  2. 2.2 Anti-Migraine Drugs Industry Drivers
  3. 2.3 Anti-Migraine Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Migraine Drugs Industry Restraints
3 Anti-Migraine Drugs Market by Company
  1. 3.1 Global Anti-Migraine Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Migraine Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Migraine Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Migraine Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Migraine Drugs Company Ranking (2024-2026)
  6. 3.6 Global Anti-Migraine Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Migraine Drugs Company Product Type and Application
  8. 3.8 Global Anti-Migraine Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Migraine Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Migraine Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Migraine Drugs Market by Type
  1. 4.1 Anti-Migraine Drugs Type Introduction
  2. 4.1.1 Ergots
  3. 4.1.2 Triptans
  4. 4.1.3 Others
  5. 4.2 Global Anti-Migraine Drugs Sales Volume by Type
  6. 4.2.1 Global Anti-Migraine Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Anti-Migraine Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Anti-Migraine Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Anti-Migraine Drugs Sales Value by Type
  10. 4.3.1 Global Anti-Migraine Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Anti-Migraine Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Anti-Migraine Drugs Sales Value Share by Type (2021-2032)
5 Anti-Migraine Drugs Market by Application
  1. 5.1 Anti-Migraine Drugs Application Introduction
  2. 5.1.1 Women
  3. 5.1.2 Men
  4. 5.2 Global Anti-Migraine Drugs Sales Volume by Application
  5. 5.2.1 Global Anti-Migraine Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anti-Migraine Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Anti-Migraine Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Anti-Migraine Drugs Sales Value by Application
  9. 5.3.1 Global Anti-Migraine Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Anti-Migraine Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Anti-Migraine Drugs Sales Value Share by Application (2021-2032)
6 Anti-Migraine Drugs Regional Sales and Value Analysis
  1. 6.1 Global Anti-Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Migraine Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Migraine Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Migraine Drugs Sales by Region (2027-2032)
  5. 6.3 Global Anti-Migraine Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Migraine Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Migraine Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Migraine Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Migraine Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Migraine Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Migraine Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Migraine Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Migraine Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Migraine Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Migraine Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Migraine Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Migraine Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Migraine Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Migraine Drugs Sales Value Share by Country, 2025 VS 2032
7 Anti-Migraine Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Migraine Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Migraine Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Migraine Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Migraine Drugs Sales by Country (2027-2032)
  6. 7.4 Global Anti-Migraine Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Migraine Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Migraine Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Migraine Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Migraine Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Migraine Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Anti-Migraine Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Endo
  8. 8.2.1 Endo Company Information
  9. 8.2.2 Endo Business Overview
  10. 8.2.3 Endo Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Endo Anti-Migraine Drugs Product Portfolio
  12. 8.2.5 Endo Recent Developments
  13. 8.3 Impax Laboratories
  14. 8.3.1 Impax Laboratories Company Information
  15. 8.3.2 Impax Laboratories Business Overview
  16. 8.3.3 Impax Laboratories Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Impax Laboratories Anti-Migraine Drugs Product Portfolio
  18. 8.3.5 Impax Laboratories Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Anti-Migraine Drugs Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Anti-Migraine Drugs Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Anti-Migraine Drugs Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Anti-Migraine Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Anti-Migraine Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Anti-Migraine Drugs Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 Merck
  56. 8.10.1 Merck Company Information
  57. 8.10.2 Merck Business Overview
  58. 8.10.3 Merck Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck Anti-Migraine Drugs Product Portfolio
  60. 8.10.5 Merck Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Anti-Migraine Drugs Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 Teva
  68. 8.12.1 Teva Company Information
  69. 8.12.2 Teva Business Overview
  70. 8.12.3 Teva Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Teva Anti-Migraine Drugs Product Portfolio
  72. 8.12.5 Teva Recent Developments
  73. 8.13 Eisai
  74. 8.13.1 Eisai Company Information
  75. 8.13.2 Eisai Business Overview
  76. 8.13.3 Eisai Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Eisai Anti-Migraine Drugs Product Portfolio
  78. 8.13.5 Eisai Recent Developments
  79. 8.14 Abbott
  80. 8.14.1 Abbott Company Information
  81. 8.14.2 Abbott Business Overview
  82. 8.14.3 Abbott Anti-Migraine Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Abbott Anti-Migraine Drugs Product Portfolio
  84. 8.14.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Migraine Drugs Value Chain Analysis
  2. 9.1.1 Anti-Migraine Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Migraine Drugs Sales Mode & Process
  6. 9.2 Anti-Migraine Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Migraine Drugs Distributors
  9. 9.2.3 Anti-Migraine Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst